Online Pharmacy health journal - Science, life, Diabetes, technology and more. Apopax focuses on recent developments of medical Drugs and Education in the world. Furthermore we are an network We are a global network
Mehr: Misc                  create pdf of this news itemprinter friendly   

Bevacizumab and glioblastoma multiforme

Glioblastoma multiforme is the most common brain tumor. According to WHO this Tumor is regarded as highly malignant and poorly visible. The name derives from the Glia "cells" of the brain. Here is also the tumor. The treatment consists of surgical reduction in tumor mass, radiation and chemotherapy.


Bevacizumab (Avastin) is an humanized, monoclonal antibody - used to treat patients with age-related macular degeneration in the eye and applied metastatic colon or rectal cancer. This antibody blocks the Vascular Endothelial Growth Factor (VEGF), a growth factor which is responsible for blood vessel formation (angiogenesis). Cancer cells grow more, therefore they need more nutrients and oxygen.

Using Bevacizumab in glioblastoma multiforme?

According to several studies and scientific, bevacizumab applied to the above-mentioned indications, even in recurrent glioblastoma multiforme [1,2]. The FDA (Food and Drug Administration) issued in 2009 multifome accelerated approval for the treatment of glioblastoma with bevacizumab. Even long before the approval, bevacizumab has been used in the U.S. and some European countries to very serious cases of glioblastoma multiforme[2]. Read more

Eingestellt von Ismail  Comments are off

Mehr: Misc                  create pdf of this news itemprinter friendly   

Good Manufacturing Practice (GMP)

GMP = Good Manufacturing Practice, Good Manufacturing Practice, established by the FDA in 1962. This sets out guidelines for quality assurance in production processes of pharmaceuticals, drugs and medical devices. There are many GMP rules with additional and complementary Guidelines:

cGMP (current U.S.)

CGMP (Community EU) Read more

Eingestellt von IsmailRead or post comments: 0